|
Caco2
|
11.6 μM
|
Tetrazolium salt (WST-8) assay
|
Download PDF
|
|
Caco2
|
14.2 μM
|
Tetrazolium salt (WST-8) assay
|
Download PDF
|
|
LN229-TS
|
0.7 μM
|
growth-delay assays, '[inhibitor] vs. response – variable slope (four parameters)' regression equation in GraphPad Prism
|
PMC8497438
|
|
LN229-TR
|
0.6 μM
|
growth-delay assays, '[inhibitor] vs. response – variable slope (four parameters)' regression equation in GraphPad Prism
|
PMC8497438
|
|
U87
|
0.2 μM
|
growth-delay assays, '[inhibitor] vs. response – variable slope (four parameters)' regression equation in GraphPad Prism
|
PMC8497438
|
|
PDX
|
0.3 μM
|
growth-delay assays, '[inhibitor] vs. response – variable slope (four parameters)' regression equation in GraphPad Prism
|
PMC8497438
|
|
HCT116 wildtype
|
2.6 µM
|
resazurin assay
|
Download PDF
|
|
LoVo-S
|
~0.5 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
LoVo-R
|
~5 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
LoVo-R (SRBC-transfected)
|
~0.5 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
LoVo-S (SRBC-depleted)
|
~5 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
HCT-15
|
3.81 ± 0.18 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
Co115, HCT-116, SW48, SW480, SW620, RKO
|
0.30 to 0.83 µm
|
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay
|
PMC3906989
|
|
4T1 cells
|
3.407 μM
|
MTT assay
|
Download PDF
|
|
HCT116-Luc-OR
|
34.7 μM
|
WST-1 Cell Proliferation and Cytotoxicity Assay Kit
|
Download PDF
|
|
CFPAC-1
|
26.49 μg/mL
|
CCK8 assays
|
Download PDF
|
|
CFPAC-1
|
15.99 μg/mL
|
CCK8 assays
|
Download PDF
|
|
PK-59
|
14.45 μg/mL
|
CCK8 assays
|
Download PDF
|
|
PK-59
|
10.03 μg/mL
|
CCK8 assays
|
Download PDF
|
|
PANC-1
|
8.66 μg/mL
|
CCK8 assays
|
Download PDF
|
|
PANC-1
|
11.36 μg/mL
|
CCK8 assays
|
Download PDF
|
|
HT29
|
9.5±2.2 µM
|
SRB assay
|
PMC8900051
|
|
HCT116
|
4.4±1.9 µM
|
SRB assay
|
PMC8900051
|
|
LoVo
|
0.9±0.3 µM
|
SRB assay
|
PMC8900051
|
|
SW620
|
1.5±0.2 µM
|
SRB assay
|
PMC8900051
|
|
PES43
|
10±1.3 µM
|
SRB assay
|
PMC8900051
|
|
4T1
|
10.23 μM
|
MTT assay
|
Download PDF
|
|
B16F10
|
12.56 μM
|
MTT assay
|
Download PDF
|
|
Renca
|
11.32 μM
|
MTT assay
|
Download PDF
|
|
PUMC-HUVEC-T1
|
15.78 μM
|
MTT assay
|
Download PDF
|
|
HCT116O MMR-deficient cells
|
27.5 μM
|
Cytotoxicity assay
|
PMC7395490
|
|
CT26
|
9.1 ± 0.7 μM
|
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay
|
Download PDF
|
|
MC38
|
10.1 ± 1.1 μM
|
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay
|
Download PDF
|
|
ID8 tumor cells
|
42.46 µg/mL
|
CCK-8 method
|
Download PDF
|
|
MC38
|
2.2 µM
|
CCK-8 assay
|
Download PDF
|
|
E. coli (DH5α)
|
97.29 µM
|
OD600 measurement (growth kinetics)
|
Download PDF
|
|
HT29-P
|
4.5 ± 0.1 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
HT29-OR
|
8.45 ± 1.08 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
LoVo-P
|
1.05 ± 0.2 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
LoVo-OR
|
10.07 ± 1.2 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
Colo201-P
|
1.47 ± 0.03 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
Colo201-OR
|
7.18 ± 1.7 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
Colo205-P
|
1.28 ± 0.3 μM
|
MTS-based cell viability assay
|
Download PDF
|
|
HCT8
|
3.23 ± 0.21 µmol/L
|
CCK-8 assay
|
Download PDF
|
|
HCT8/L-OHP
|
46.08 ± 5.27 µmol/L
|
CCK-8 assay
|
Download PDF
|
|
HCT116
|
3.82 μM
|
CCK8 assay
|
PMC12532874
|
|
SW480
|
4.99 μM
|
CCK8 assay
|
PMC12532874
|
|
SPDO1P
|
2.7940 ± 0.3993 µM
|
CCK8 assay
|
PMC11318189
|
|
SPDO1LM
|
5.6873 ± 0.4514 µM
|
CCK8 assay
|
PMC11318189
|
|
AGS
|
25.7033 ± 1.1197 µM
|
CCK8 assay
|
PMC11318189
|
|
NCI-N87-2D
|
4.6780 ± 0.3169 µM
|
CCK8 assay
|
PMC11318189
|
|
NCI-N87-3D spheroids
|
7.8373 ± 1.1069 µM
|
CCK8 assay
|
PMC11318189
|
|
Hepa 1-6
|
0.9 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
97H
|
0.25 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
3B
|
0.25 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
Hepa 1-6 –OXA
|
5 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
97H-OXA
|
5 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
3B-OXA
|
5 mmol/L
|
Cell Counting Kit-8 (CCK-8) assay
|
PMC9868681
|
|
SGC-7901
|
15.87 ± 0.27 µg/mL (48h); 14.17 ± 0.14 µg/mL (72h)
|
MTT assay
|
PMC8712509
|
|
SKOV-3
|
5.9±1.3 μM
|
MTT assay
|
PMC8375242
|
|
SKOV-3
|
7.5±1.8 μM
|
MTT assay
|
PMC8375242
|
|
CT-26
|
4.1±0.7 μM
|
MTT assay
|
PMC8375242
|
|
A549
|
6.7±1.8 μM
|
MTT assay
|
PMC8375242
|
|
A549R
|
2.4±0.6 μM
|
MTT assay
|
PMC8375242
|
|
LO-2
|
4.8±0.7 μM
|
MTT assay
|
PMC8375242
|
|
HCT116 WT
|
0.72 ±0.18 μM
|
MTT assay
|
Download PDF
|
|
HCT116 WT/OxR
|
>10 μM
|
MTT assay
|
Download PDF
|
|
HCT116 p53KO
|
2.37 ±0.45 μM
|
MTT assay
|
Download PDF
|
|
huTGO1
|
31.57 ±0.06 µM
|
MTS assay
|
PMC6279812
|
|
huTGO2
|
17.09 ±0.04 µM
|
MTS assay
|
PMC6279812
|
|
huTGO1
|
7.93 ±0.05 µM
|
MTS Assay
|
PMC6279812
|
|
huTGO2
|
1.74 ±0.07 µM
|
MTS Assay
|
PMC6279812
|
|
HCT116
|
8.34 µM
|
MTT staining method
|
PMC9844232
|
|
HCT116
|
1.98 ± 0.22 μM
|
MTT assay
|
Download PDF
|
|
HCT116-OXAR
|
18.9 ± 2.7 μM
|
MTT assay
|
Download PDF
|
|
KYSE-150
|
3.19 ug/mL
|
CCK-8 assay
|
Download PDF
|
|
Eca-9706
|
3.03 ug/mL
|
CCK-8 assay
|
Download PDF
|
|
H22 cells
|
21.52±0.88 μM
|
CCK-8 assay
|
PMC11871924
|
|
VX2 cells
|
24.41±2.07 µM
|
Thiazolyl Blue (MTT) assay
|
PMC11871924
|
|
MKN45
|
6.8745 μM
|
Cell viability measurement by luminescence
|
Download PDF
|
|
Peritoneal Macrophages
|
13.624 μM
|
Cell viability measurement by luminescence
|
Download PDF
|
|
HCT116 cells
|
43.22 μM
|
CCK-8 assay
|
PMC11774109
|
|
SW480
|
2.69 ± 0.15 µM
|
CCK-8 assay
|
Download PDF
|
|
SW620
|
3.98 ± 0.29 µM
|
CCK-8 assay
|
Download PDF
|
|
HT29
|
13.38 ± 2.1 µM
|
CCK-8 assay
|
Download PDF
|
|
HCT116
|
4.69 ± 0.84 µM
|
CCK-8 assay
|
Download PDF
|
|
T84
|
3.45 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
SW480
|
1.52 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
HT29
|
1.19 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
HCT15
|
1.62 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
HCT116
|
1.98 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
RKO
|
1.56 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
MC38
|
1.63 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
MC38-L(-)
|
0.55 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
HepG2
|
1.21 µM
|
Sulforhodamine B (SRB) assay
|
PMC10898605
|
|
Cancer cell lines (High Ferroptosis Score group)
|
460.3 μM/L
|
Sanger GDSC2
|
Download PDF
|
|
Cancer cell lines (Low Ferroptosis Score group)
|
333.2 μM/L
|
Sanger GDSC2
|
Download PDF
|
|
LPHC-6 cells
|
102.70 µM/mL (24h), 43.82 µM/mL (48h), 24.59 µM/mL (72h)
|
MTT or CCK8 assay
|
PMC12522666
|
|
LS180 cells
|
0.8 ± 0.04 µM (firefly), 0.8 ± 0.01 µM (Renilla)
|
Dual-Glo Luciferase assay system for luminescence declines (firefly and Renilla)
|
Download PDF
|
|
Caco-2 cells
|
0.98 μg/ml
|
MTT test, plates were read at 592 nm, data analyzed and plotted using GraphPad Prism 9, nonlinear regression to fit the titration curves and calculate IC50 values.
|
Download PDF
|
|
SW620
|
15.8 μg/ml
|
MTS assay
|
Download PDF
|
|
SK-MEL 28
|
13.74 ± 0.24 µM
|
Resazurin metabolic activity assay, nonlinear regression analysis.
|
Download PDF
|
|
B16F10
|
21.04 ± 1.0 µM
|
Resazurin metabolic activity assay, nonlinear regression analysis.
|
Download PDF
|
|
B16F0
|
37.04 ± 1.34 µM
|
Resazurin metabolic activity assay, nonlinear regression analysis.
|
Download PDF
|
|
HCT116
|
10 mM
|
CCK-8 cytotoxicity assay
|
Download PDF
|
|
SW480
|
20 mM
|
CCK-8 cytotoxicity assay
|
Download PDF
|
|
SW48
|
134 µM
|
MTT assay
|
PMC12329872
|
|
SW480
|
39 µM
|
MTT assay
|
PMC12329872
|
|
SW1116
|
132 µM
|
MTT assay
|
PMC12329872
|
|
Caco-2
|
100 µM
|
MTT assay
|
PMC12329872
|
|
AGS cells
|
10 µmol/L
|
MTT assay
|
PMC7029347
|
|
HCT116
|
20.20 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480
|
19.40 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP
|
114.9 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP
|
109.8 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (Vector)
|
116.5 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (si-OIP5-AS1)
|
54.96 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (sh-OIP5-AS1)
|
196.6 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (Vector)
|
114.1 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (si-OIP5-AS1)
|
52.33 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (sh-OIP5-AS1)
|
186.7 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (miR-NC)
|
117.3 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (miR-137-mimics)
|
52.87 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HCT116/L-OHP (miR-137-inhibitor)
|
202.0 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (miR-NC)
|
112.5 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (miR-137-mimics)
|
48.62 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
SW480/L-OHP (miR-137-inhibitor)
|
196.1 μg/mL
|
Cell counting kit-8
|
PMC7152514
|
|
HT29oxR
|
6.0 μM
|
Cell Counting Kit (CCK)-8 assay
|
PMC6838436
|
|
HCT116
|
3.4 μM
|
Cell Counting Kit (CCK)-8 assay
|
PMC6838436
|
|
HT29
|
3.1 μM
|
Cell Counting Kit (CCK)-8 assay
|
PMC6838436
|
|
HT29 WT
|
8.2 µM
|
CellTiter-Glo® 2.0 Cell Viability Assay
|
Download PDF
|
|
HT29 Oxa-R
|
35.3 µM
|
CellTiter-Glo® 2.0 Cell Viability Assay
|
Download PDF
|
|
SW480 WT
|
5.1 µM
|
CellTiter-Glo® 2.0 Cell Viability Assay
|
Download PDF
|
|
SW480 Oxa-R
|
24.8 µM
|
CellTiter-Glo® 2.0 Cell Viability Assay
|
Download PDF
|
|
BT-549
|
1.5 ± 0.5 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
SUM159
|
4.7 ± 2.3 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
HCC38
|
4.3 ± 2.5 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
MDA-MB-436
|
5.7 ± 4.04 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
OVSAHO
|
4.7 ± 1.5 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
OVCAR-8
|
2.83 ± 0.15 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
DU 145
|
3.0 ± 0.006 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
PC-3
|
2.5 ± 0.26 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
22Rv1
|
4.83 ± 2.25 µM
|
Celigo® imaging cytometer, dual staining with propidium iodide (PI) and calcein-AM, quantification of live and dead cells, calculation of growth percentage, and plotting against drug concentrations.
|
Download PDF
|
|
AGS
|
24.06 μM
|
Cell Counting Kit-8 assay
|
PMC11962845
|
|
AGS-KRT80
|
36.18 μM
|
Cell Counting Kit-8 assay
|
PMC11962845
|
|
SGC7901
|
34.71 μM
|
Cell Counting Kit-8 assay
|
PMC11962845
|
|
SGC7901-KRT80
|
45.67 μM
|
Cell Counting Kit-8 assay
|
PMC11962845
|
|
AGS
|
29.54
|
CCK-8 assay
|
Download PDF
|
|
HGC27
|
15.35
|
CCK-8 assay
|
Download PDF
|
|
HCT116 Oxa-R (SIRT1 knockdown)
|
271.4 μM
|
MTS assay
|
PMC11924001
|
|
HCT116 Oxa-R (SIRT1 overexpression)
|
100.5 μM
|
MTS assay
|
PMC11924001
|
|
MCF-10A
|
42.10 µM
|
MTT assay, calculated using GraphPad V.8 program
|
Download PDF
|
|
MCF-7
|
56.85 µM
|
MTT assay, calculated using GraphPad V.8 program
|
Download PDF
|
|
MDA-MB231
|
21.91 µM
|
MTT assay, calculated using GraphPad V.8 program
|
Download PDF
|
|
T47D
|
67.35 µM
|
MTT assay, calculated using GraphPad V.8 program
|
Download PDF
|
|
MDA-MB231resistant
|
54.9 µM
|
MTT assay, calculated using GraphPad V.8 program
|
Download PDF
|
|
HCT116
|
32±3.6 uM
|
MTT assay
|
Download PDF
|
|
HT-29
|
2.57±0.89 uM
|
MTT assay
|
Download PDF
|
|
LoVo
|
0.58±0.13 uM
|
MTT assay
|
Download PDF
|
|
Colo205
|
2.6±0.52 uM
|
MTT assay
|
Download PDF
|
|
AsPC-1 organoids
|
>1 mM
|
Viability dose-response data
|
Download PDF
|
|
MIA PaCa-2 organoids
|
646 µM
|
Viability dose-response data
|
Download PDF
|
|
AsPC-1 organoids
|
1695 µM (viability), 23.55 µM (residual viable disease)
|
Viability and cumulative viable area
|
Download PDF
|
|
A2780
|
0.15 μM
|
5-day MTT assay
|
Download PDF
|
|
HT29 cells
|
0.343 mg/mL
|
MTT assay
|
Download PDF
|
|
Colo320
|
8.21 µM
|
XTT assay, fit spline/LOWESS regression analysis
|
Download PDF
|
|
MDA-MB-231 cells
|
0.05 µg/mL
|
In vitro cytotoxicity assay
|
Download PDF
|
|
CT26 cells
|
24.14 µM
|
Cytotoxicity assay
|
Download PDF
|
|
HepG2
|
15.81 µM
|
Cell Counting Kit‑8 (CCK‑8) assay
|
PMC12101187
|
|
PLC/PRF/5
|
22.56 µM
|
Cell Counting Kit‑8 (CCK‑8) assay
|
PMC12101187
|
|
Hepa1-6
|
16.79 µM
|
Cell Counting Kit‑8 (CCK‑8) assay
|
PMC12101187
|
|
AsPC-1
|
10.2 µM
|
MTT assay, non-linear model platform
|
Download PDF
|
|
BxPC-3
|
10.8 µM
|
MTT assay, non-linear model platform
|
Download PDF
|
|
PANC-1
|
98.7 µM
|
MTT assay, non-linear model platform
|
Download PDF
|
|
LNCaP
|
1.06 µM
|
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS reagent), measured via absorbance at 490 nm. CompuSyn software was used for analysis.
|
PMC4021534
|
|
PC3
|
5.66 µM
|
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS reagent), measured via absorbance at 490 nm. CompuSyn software was used for analysis.
|
PMC4021534
|
|
DU145
|
9.06 µM
|
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS reagent), measured via absorbance at 490 nm. CompuSyn software was used for analysis.
|
PMC4021534
|
|
OCUM-2M
|
1.4 mM
|
MTT assay
|
PMC3833223
|
|
OCUM-2M/SP
|
3.9 mM
|
MTT assay
|
PMC3833223
|
|
HCT-116
|
52 µM
|
WST-1 reagent, measuring reduction of tetrazolium salts to formazan by mitochondrial dehydrogenase enzymes
|
Download PDF
|
|
HCT-116-ROx
|
96 µM
|
WST-1 reagent, measuring reduction of tetrazolium salts to formazan by mitochondrial dehydrogenase enzymes
|
Download PDF
|
|
ciPTEC
|
51 µM
|
Relative cell count (RCC) using CASY®cell counter
|
Download PDF
|
|
HROP68Tu2
|
1.55 μM
|
crystal violet assay
|
Download PDF
|
|
T3M4 CTRL
|
2.27 ± 2.3 µM
|
Crystal violet assay, non-linear regression using GraphPad Prism 9
|
Download PDF
|
|
T3M4 DDB2-low
|
2.36 ± 2.4 µM
|
Crystal violet assay, non-linear regression using GraphPad Prism 9
|
Download PDF
|
|
Capan-2 CTRL
|
36.77 ± 12.6 µM
|
Crystal violet assay, non-linear regression using GraphPad Prism 9
|
Download PDF
|
|
Capan-2 DDB2-high
|
13.75 ± 4.12 µM
|
Crystal violet assay, non-linear regression using GraphPad Prism 9
|
Download PDF
|
|
CRC-PDOs
|
1.37 to 100 mM
|
cell viability assay
|
Download PDF
|
|
LoVo
|
3.27 ± 0.37 mM
|
MTT assay
|
Download PDF
|
|
HCT116
|
2.09 ± 0.56 mM
|
MTT assay
|
Download PDF
|
|
SW620
|
8.74 ± 1.49 mM
|
MTT assay
|
Download PDF
|
|
SGC7901 (Arg388-transfected)
|
12.83 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
SGC7901 (Gly388-transfected)
|
10.46 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
SGC7901 (mock)
|
5.77 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
SGC7901 (NC)
|
5.12 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
BGC803 (Arg388-transfected)
|
11.67 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
BGC803 (Gly388-transfected)
|
6.86 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
BGC803 (mock)
|
1.96 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
BGC803 (NC)
|
2.27 μg
|
CCK-8 proliferation assay
|
PMC7577822
|
|
rα7 nAChRs
|
200 µM
|
2-electrode voltage clamp recordings of ACh- and nicotine-evoked currents
|
PMC10408732
|
|
HCT116 WT
|
2.8 µM (48h), 1.6 µM (72h)
|
biomass staining via crystal violet
|
PMC6412115
|
|
HCT116 p53−/−
|
6.6 µM (72h)
|
biomass staining via crystal violet
|
PMC6412115
|
|
NCI-H2818
|
3.47 µM
|
Sulphorodamine B (SRB) assay
|
Download PDF
|
|
NCI-H2795
|
18.23 µM
|
Sulphorodamine B (SRB) assay
|
Download PDF
|
|
NCI-H2731
|
9.77 µM
|
Sulphorodamine B (SRB) assay
|
Download PDF
|
|
DLD1 cells
|
4.6 µM
|
MTT test
|
Download PDF
|
|
HCT-8
|
300.067 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT-8
|
91.426 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT-8
|
36.027 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT116
|
156.498 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT116
|
87.844 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT116
|
43.886 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW480
|
225.824 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW480
|
80.096 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW480
|
44.435 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW620
|
250.923 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW620
|
87.636 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
SW620
|
43.780 µmol/L
|
CCK-8 assay
|
PMC9763735
|
|
HCT8-LOHP-shFASN
|
8.69 µmol/L
|
MTT assay
|
Download PDF
|
|
HCT116-LOHP-shFASN
|
13.7 µmol/L
|
MTT assay
|
Download PDF
|
|
HCT8-FASN
|
7.79 µmol/L
|
MTT assay
|
Download PDF
|
|
HCT116-FASN
|
7.60 µmol/L
|
MTT assay
|
Download PDF
|
|
CT-26
|
7.55±1.72 µg/mL
|
MTT assay
|
PMC5391159
|
|
HCT-116
|
1.06±0.57 µg/mL
|
MTT assay
|
PMC5391159
|
|
KB
|
30.58 µM
|
MTS assay
|
PMC4069133
|
|
KB
|
5.61 µM
|
MTS assay
|
PMC4069133
|
|
OSC-19
|
78.47 µM
|
MTS assay
|
PMC4069133
|
|
OSC-19
|
69.23 µM
|
MTS assay
|
PMC4069133
|
|
OSC-20
|
60.25 µM
|
MTS assay
|
PMC4069133
|
|
OSC-20
|
55.3 µM
|
MTS assay
|
PMC4069133
|
|
HSC-3
|
15.29 µM
|
MTS assay
|
PMC4069133
|
|
HSC-3
|
5.2 µM
|
MTS assay
|
PMC4069133
|
|
HSC-4
|
18.66 µM
|
MTS assay
|
PMC4069133
|
|
HSC-4
|
7.62 µM
|
MTS assay
|
PMC4069133
|
|
AGS
|
60.98 µM
|
CCK-8 assay
|
PMC8068497
|
|
MKN45
|
70.57 µM
|
CCK-8 assay
|
PMC8068497
|
|
AGS/OXA
|
212.8 µM
|
CCK-8 assay
|
PMC8068497
|
|
MKN45/OXA
|
289.2 µM
|
CCK-8 assay
|
PMC8068497
|
|
PDC cells
|
2.32 μg/mL
|
Cell Counting Kit-8 (CCK-8) assay, absorbance measured at 490 nm, IC50 values determined using GraphPad Prism software.
|
PMC12667283
|
|
PDC-R cells
|
21.41 μg/mL
|
Cell Counting Kit-8 (CCK-8) assay, absorbance measured at 490 nm, IC50 values determined using GraphPad Prism software.
|
PMC12667283
|
|
shNORAD PDC-R cells
|
3.82 μg/mL
|
Cell Counting Kit-8 (CCK-8) assay, absorbance measured at 490 nm, IC50 values determined using GraphPad Prism software.
|
PMC12667283
|
|
DPC-X1
|
13.26 μmol/L
|
CCK-8 assay
|
PMC10198051
|
|
MHCC97L-Oxa
|
66.67 ± 9.01 μmol/L
|
CCK8
|
Download PDF
|
|
Hep3B-Oxa
|
19.21 ± 2.69 μmol/L
|
CCK8
|
Download PDF
|
|
MHCC97L-Src
|
108.71 ± 11.24 μmol/L
|
CCK8
|
Download PDF
|
|
Hep3B-Src
|
27.01 ± 4.59 μmol/L
|
CCK8
|
Download PDF
|
|
MHCC97L (ABCG1 silenced)
|
8.41 ± 2.09 μmol/L
|
CCK8
|
Download PDF
|
|
MHCC97L-Mock
|
25.59 ± 5.82 μmol/L
|
CCK8
|
Download PDF
|
|
MHCC97L-Src-ABCG1-Sh1
|
40.43 ± 8.12 μmol/L
|
CCK8
|
Download PDF
|
|
MHCC97L-Src (mock-treated)
|
103.71 ± 8.74 μmol/L
|
CCK8
|
Download PDF
|
|
mCRC organoids
|
33.56 μM
|
3D Reagent viability assay, luminescence detection, GraphPad Prism 8 for IC50 calculation
|
Download PDF
|
|
HCT116
|
6.315 μM
|
CCK-8 assay
|
PMC10600807
|
|
HCT116-OxR
|
64.2 μM
|
CCK-8 assay
|
PMC10600807
|
|
HCT8
|
1.064 µM
|
CCK-8 assay
|
PMC10600807
|
|
HCT8-OxR
|
6.241 μM
|
CCK-8 assay
|
PMC10600807
|
|
HCT116
|
Increased
|
CCK-8 assay
|
PMC10600807
|
|
HCT8
|
Increased
|
CCK-8 assay
|
PMC10600807
|
|
HCT116-OxR
|
Decreased
|
CCK-8 assay
|
PMC10600807
|
|
HCT8-OxR
|
Decreased
|
CCK-8 assay
|
PMC10600807
|
|
SKOV3
|
25 µg/mL
|
MTT assay
|
Download PDF
|
|
OVCAR3
|
12 µg/mL
|
MTT assay
|
Download PDF
|
|
LoVo
|
19.51 ± 1.02 μM
|
MTT assay
|
PMC11635512
|
|
HCT-116
|
13.48 ± 0.87 μM
|
MTT assay
|
PMC11635512
|
|
A549
|
82.64 ± 1.65 μM
|
MTT assay
|
PMC11635512
|
|
HCT-116
|
1.6 ± 0.17 μM
|
MTS assay
|
Download PDF
|
|
HT-29
|
8.0 ± 2.0 μM
|
MTS assay
|
Download PDF
|
|
SW-480
|
6.0 ± 2.08 μM
|
MTS assay
|
Download PDF
|
|
CaCO2
|
2.7 ± 0.15 μM
|
MTS assay
|
Download PDF
|
|
LS174T
|
2.87 ± 1.27 μM
|
MTS assay
|
Download PDF
|
